Arginine Vasopressin (AVP)
Introduction
Arginine Vasopressin (Avp) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@rotzinger2020]
<div class="infobox-header">Arginine Vasopressin (AVP)</div> [@engelmann2021]
<div class="infobox-row"><strong>Gene:</strong> [AVP](/proteins/avp-protein)</div> [@albers2019]
<div class="infobox-row"><strong>UniProt ID:</strong> [P01178](https://www.uniprot.org/uniprot/P01178)</div> [@krause2018]
<div class="infobox-row"><strong>Molecular Weight:</strong> 4.7 kDa (preprovasopressin), 1.1 kDa (mature peptide)</div>
<div class="infobox-row"><strong>Amino Acid Length:</strong> 9 amino acids (mature peptide)</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Secretory vesicles, dense-core granules</div>
<div class="infobox-row"><strong>Protein Family:</strong> Vasopressin/oxytocin family (cysteine-knot peptide family)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> AD, PD, HD, SIADH, Diabetes Insipidus, Depression, Autism, PTSD</div>
</div>
Overview
Arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), is a 9-amino acid neuropeptide that plays essential roles in water retention, blood pressure regulation, and social behavior. First isolated in 1956 and synthesized in 1958, AVP is produced in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus and released from the posterior pituitary gland into systemic circulation. Beyond its peripheral endocrine functions, AVP acts as a neurotransmitter and neuromodulator throughout the brain, influencing social cognition, pair bonding, aggression, stress responses, and circadian rhythms. AVP signals through three G protein-coupled receptors (V1a, V1b, and V2), with V1a and V1b mediating central nervous system effects. The AVP system is critically involved in both physiological homeostasis and the pathophysiology of stress-related neurodegenerative and psychiatric disorders.
Normal Function
Osmoregulation and Water Balance
AVP is the primary regulator of body water homeostasis. Osmoreceptors in the hypothalamic OVLT (organum vasculosum of the lamina terminalis) sense plasma osmolality and stimulate AVP release when osmolality increases above a threshold (~280 mOsm/kg). AVP binds to V2 receptors in the renal collecting duct, promoting water reabsorption through aquaporin-2 channel insertion. This antidiuretic effect is crucial for maintaining plasma osmolality and blood volume. AVP also causes vasoconstriction through V1a receptor activation, contributing to blood pressure regulation.
Stress Response Coordination
AVP, along with CRH, coordinates behavioral and physiological responses to stress. AVP [neurons](/entities/neurons) in the PVN are activated by various stressors, and AVP acts synergistically with CRH to stimulate ACTH release from the pituitary. In the amygdala and bed nucleus of the stria terminalis (BNST), AVP modulates anxiety-related behavior and fear responses. The peptide influences stress coping strategies, with different AVP receptor subtypes mediating distinct behavioral outcomes. Chronic stress can lead to AVP system dysregulation, contributing to stress-related pathologies.
Social Cognition and Behavior
AVP plays critical roles in social recognition, pair bonding, aggression, and mating behavior. In the medial amygdala and BNST, AVP influences social memory formation and social recognition. Species-typical patterns of AVP receptor expression determine whether the peptide promotes prosocial or agonistic behaviors. In prairie voles, AVP receptor expression patterns in the ventral pallidum are critical for pair bonding. AVP also modulates paternal behavior, social vigilance, and responses to social novelty. The peptide interacts with oxytocin systems to coordinate social behaviors.
Circadian Regulation
AVP neurons in the suprachiasmatic nucleus (SCN) serve as the output signal of the central circadian clock. AVP is released in a circadian rhythm, with peak levels during the subjective day in nocturnal rodents. SCN-derived AVP influences circadian rhythms in peripheral organs and coordinates daily physiological rhythms. Disruption of AVP signaling may contribute to circadian rhythm disturbances in neurodegenerative diseases.
Cardiovascular Regulation
Beyond its direct vasoconstrictive effects, AVP modulates cardiovascular function through central actions. AVP influences baroreceptor reflex sensitivity and can affect heart rate and cardiac output. The peptide interacts with renin-angiotensin systems to coordinate blood pressure regulation. AVP deficiency or excess can contribute to cardiovascular disorders including hypertension and heart failure.
Role in Neurodegenerative Diseases
Alzheimer's Disease
AVP alterations contribute to cognitive and behavioral symptoms in Alzheimer's disease. Studies show elevated AVP levels in the CSF of AD patients, potentially reflecting hypothalamic dysfunction. AVP can modulate [amyloid-beta](/proteins/amyloid-beta) (Aβ) toxicity; the peptide has both protective and detrimental effects depending on concentration and brain region. AVP influences memory consolidation, with V1a receptor activation generally impairing memory in most paradigms. Circadian AVP rhythm disruption in the SCN contributes to sleep-wake disturbances common in AD. The peptide may also modulate [tau](/proteins/tau) pathology through effects on protein phosphorylation.
Parkinson's Disease
Parkinson's disease involves multiple AVP system abnormalities. Dopaminergic degeneration alters hypothalamic AVP secretion, contributing to autonomic dysfunction including orthostatic hypotension. AVP levels may be abnormal in the substantia nigra and striatum of PD patients. The peptide modulates dopaminergic signaling in the basal ganglia, potentially influencing motor control and levodopa response. AVP may also contribute to non-motor symptoms including depression, anxiety, and sleep disorders in PD.
Huntington's Disease
HD involves early AVP system dysfunction. Mutant [huntingtin](/proteins/huntingtin-protein) (mHTT) affects AVP-expressing neurons in the hypothalamus, potentially contributing to hypothalamic pathology and circadian disturbances. Studies show altered AVP expression in the HD brain and CSF. The peptide may contribute to irritability, aggression, and other behavioral symptoms in HD. AVP receptor antagonists have shown some benefits in animal models of HD.
Circadian Disorders
AVP is central to circadian rhythm generation and disruption. In neurodegenerative diseases characterized by circadian disturbances (AD, PD, HD), AVP system dysfunction may be both a cause and consequence of circadian disruption. Loss of AVP rhythm amplitude correlates with cognitive decline in AD. Therapeutic strategies targeting AVP receptors may help restore circadian function in neurodegenerative disorders.
Therapeutic Implications
V1a Receptor Antagonists
- SRX246: A selective V1a antagonist being developed for stress-related disorders including PTSD and anxiety.
- Nelivaptan: A V1a antagonist with potential CNS applications.
- Relcovaptan: A V1a antagonist explored for cardiovascular and CNS applications.
V1b Receptor Antagonists
- SSR149415: A V1b antagonist with anxiolytic and antidepressant-like effects in preclinical models.
- A-987180: A selective V1b antagonist being developed for depression and stress disorders.
V2 Receptor Agonists
- Desmopressin (DDAVP): A V2-selective agonist used to treat diabetes insipidus and nocturnal enuresis. Limited CNS penetration.
- Carbetocin: A long-acting oxytocin/vasopressin receptor agonist with potential CNS applications.
Peptide Analogs
- Selective V1a Agonists: For potential use in memory enhancement or social cognition.
- Selective V1b Agonists: For potential use in stress resilience.
- Brain-Penetrant Analogs: Under development for CNS disorders.
Non-Pharmacological Approaches
- Light Therapy: Can normalize circadian AVP rhythms.
- Sleep Hygiene: Improves AVP rhythm stability.
- Stress Reduction: Reduces chronic AVP system activation.
Animal Models
- AVP Knockout Mice: Display diabetes insipidus, altered stress responses, and social behavior deficits.
- V1a Receptor Knockout Mice: Show impaired social recognition, altered anxiety, and reduced aggression.
- V1b Receptor Knockout Mice: Display reduced stress reactivity and altered social behavior.
- Transgenic AVP Overexpression: Leads to hypertension, increased aggression, and altered social behavior.
Research Directions
Current research focuses on: (1) developing brain-penetrant AVP receptor ligands; (2) understanding AVP interactions with neuropathology in AD, PD, HD; (3) exploring AVP-targeted therapies for circadian disorders; (4) investigating AVP as a biomarker for hypothalamic dysfunction; (5) developing non-peptide AVP receptor ligands with improved pharmacological profiles.
See Also
- [Proteins Index](/proteins)
- [Genes Index](/genes)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [Hypothalamus](/brain-regions/hypothalamus)
- [Suprachiasmatic Nucleus](/cell-types/suprachiasmatic-nucleus)
- [Amygdala](/brain-regions/amygdala)
- [Neuropeptide Y](/proteins/neuropeptide-y-protein)
- [Somatostatin](/proteins/somatostatin-protein)
- [CRH](/proteins/crh-protein)
- [Galanin](/proteins/galanin-protein)
External Links
- [UniProt: Vasopressin (AVP)](https://www.uniprot.org/uniprot/P01178)
- [IUPHAR/BPS Guide to Pharmacology: Vasopressin Receptors](https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35)
Background
The study of Arginine Vasopressin (Avp) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Caldwell HK, Wersinger SR, Young WS, Oxytocin and vasopressin: Social neuropeptides (2022)](https://doi.org/10.1177/107385840200800403)
[Rotzinger S, Lovejoy DA, Tan LA, Behavioral effects of neuropeptides in neurodegenerative diseases (2020)](https://doi.org/10.1016/j.pnpbp.2020.109879)
[Engelmann M, Landgraf R, Wotjak CT, The hypothalamic-neurohypophyseal system and social behavior (2021)](https://doi.org/10.1016/j.neubiorev.2020.10.010)
[Albers HE, The regulation of social recognition, social anxiety and aggressive behavior (2019)](https://doi.org/10.1016/j.brainres.2018.11.024)
[Krause EG, Sannino SB, Hashimoto H, Vasopressin and social behavior (2018)](https://doi.org/10.1016/j.conb.2018.02.006)